Weight Loss
Page 1 • 2 itemsGain critical insights into the global weight loss drug market. Track pipeline advancements, regulatory approvals, and investment opportunities.
Neurocrine Biosciences Begins Phase 1 Trial of NBIP-2118 for Obesity Treatment
Neurocrine Biosciences initiates first-in-human Phase 1 trial for NBIP-2118, a novel CRF2 receptor agonist targeting obesity through non-incretin mechanisms.
Zealand Pharma's Survodutide Achieves 16.6% Weight Loss in Phase 3 Obesity Trial, Outperforming Current GLP-1 Therapies
Zealand Pharma announces survodutide achieved 16.6% weight loss in Phase 3 SYNCHRONIZE-1 trial, potentially exceeding Wegovy and Zepbound efficacy rates.